<DOC>
	<DOC>NCT01961167</DOC>
	<brief_summary>The primary objective of the GORE® PI-13-05 clinical study is to evaluate the safety and efficacy of PI 13-05 for the treatment of arterial occlusive disease in patients with de novo or restenotic lesions in the common and/or external iliac arteries.</brief_summary>
	<brief_title>Evaluation of the GORE® PI 13-05 Device for the Treatment of Occlusive Disease in the Common and External Iliac Arteries</brief_title>
	<detailed_description />
	<mesh_term>Arterial Occlusive Diseases</mesh_term>
	<criteria>Patient is at least 18 years old; Patient is male, infertile female, or female of childbearing potential practicing an acceptable method of preventing pregnancy; Patient or legal representative is willing to give written informed consent; Patient is capable of complying with protocol requirements, including all followup visits; Patient has symptomatic claudication or rest pain without tissue loss (Rutherford Categories 24). Patient has de novo or restenotic target lesion(s) in the common and/or external iliac artery Patient has a life expectancy of less than 1 year; Patient has a known allergy to stent graft components, including stainless steel or heparin; Patient has a known intolerance to antiplatelet, anticoagulant, or thrombolytic medications that would prevent compliance with the protocol; Patient has a condition (unrelated to the study) that is expected to require indefinite, or lifelong, anticoagulation Patient has had vascular access / catheterization in the lower extremity within 30 days of study enrollment; Patient has had a previous or planned coronary intervention within 30 days prior to enrollment in this study or required at time of study procedure; Patient has had a previous or planned bypass surgery in the target leg, or a bypass that occurs at the time of the study procedure; Patient is currently participating in this or another investigative clinical study. Patient has evidence of angiographically visible thrombus within or adjacent to the target lesion(s); Patient has aneurysmal dilation proximal or distal to the target lesion(s) that would interfere with the placement of the device; Patient has a target lesion requiring atherectomy or any ablative device to facilitate stent delivery; Patient has a target lesion situated in such a way that an implanted device will prevent blood flow or perfusion to the internal iliac artery if patent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>